Published in Int J Clin Exp Pathol on June 14, 2011
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling. J Pathol (2011) 1.27
mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med (2015) 0.93
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations. Mech Ageing Dev (2012) 0.91
Dissociation of the pharmacological effects of THC by mTOR blockade. Neuropsychopharmacology (2013) 0.90
A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience (2014) 0.89
EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch (2012) 0.88
Topical rapamycin (sirolimus) for facial angiofibromas. Indian Dermatol Online J (2013) 0.88
Primary ductal adenocarcinoma of the lacrimal sac: the first reported case. Int J Clin Exp Pathol (2013) 0.84
mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis. PLoS One (2015) 0.83
Quality control systems in cardiac aging. Ageing Res Rev (2015) 0.83
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer (2012) 0.83
Pharmacologically Improved Contractility Protects Against Aortic Dissection in Mice With Disrupted Transforming Growth Factor-β Signaling Despite Compromised Extracellular Matrix Properties. Arterioscler Thromb Vasc Biol (2016) 0.82
Lumen LPS inhibits HCO3(-) absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ exchange. Am J Physiol Renal Physiol (2013) 0.81
mTOR: a potential therapeutic target in osteoarthritis? Drugs R D (2015) 0.81
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. J Cancer Res Clin Oncol (2011) 0.81
Syncytiotrophoblast Functions and Fetal Growth Restriction during Placental Malaria: Updates and Implication for Future Interventions. Biomed Res Int (2015) 0.80
Physical and genetic-interaction density reveals functional organization and informs significance cutoffs in genome-wide screens. Proc Natl Acad Sci U S A (2013) 0.80
Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. World J Diabetes (2015) 0.80
Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis. J Mol Genet Med (2013) 0.78
Nutrition strategies to improve physical capabilities in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am (2011) 0.78
Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients. Oncol Lett (2014) 0.76
P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Cell size and fat content of dietary-restricted Caenorhabditis elegans are regulated by ATX-2, an mTOR repressor. Proc Natl Acad Sci U S A (2016) 0.75
Bunched and Madm Function Downstream of Tuberous Sclerosis Complex to Regulate the Growth of Intestinal Stem Cells in Drosophila. Stem Cell Rev (2015) 0.75
Rapamycin Prevents cyclophosphamide-induced Over-activation of Primordial Follicle pool through PI3K/Akt/mTOR Signaling Pathway in vivo. J Ovarian Res (2017) 0.75
MYCing and YAPing the escape of tumor cell growth arrest after chronic PI3K/mTOR inhibition. J Thorac Dis (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem (1999) 14.59
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
TOR, a central controller of cell growth. Cell (2000) 10.41
Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 9.40
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15
Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol (2005) 7.11
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (1998) 6.79
Phosphorylation and activation of p70s6k by PDK1. Science (1998) 6.53
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Rheb binds and regulates the mTOR kinase. Curr Biol (2005) 6.09
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol (2004) 5.46
The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci (2006) 5.11
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol (2004) 4.70
mTOR, translation initiation and cancer. Oncogene (2006) 4.68
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J (2001) 4.40
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol (2003) 3.97
eIF4E--from translation to transformation. Oncogene (2004) 3.78
mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol (2004) 3.72
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 3.59
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem (2005) 3.56
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol (2005) 3.24
mTOR and cancer therapy. Oncogene (2006) 3.07
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90
Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem (2000) 2.86
Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem (2005) 2.84
Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2002) 2.69
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes (2004) 2.64
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol (1996) 2.22
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res (2007) 2.21
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res (2006) 2.21
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res (2003) 2.08
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res (2006) 1.84
Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci U S A (2000) 1.77
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol (2003) 1.75
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 1.72
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun (2004) 1.69
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer (2006) 1.68
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
The biology behind mTOR inhibition in sarcoma. Oncologist (2007) 1.54
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52
Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res (2006) 1.46
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res (2001) 1.41
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer (2005) 1.41
All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle (2007) 1.38
Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene (2002) 1.36
mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. Cell Cycle (2010) 1.31
Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol (1999) 1.30
Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood (2002) 1.26
Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol (2009) 1.25
Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol (2004) 1.25
Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res (1999) 1.23
The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol (2003) 1.22
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett (2005) 1.22
mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle (2005) 1.19
mTOR signaling contributes to chondrocyte differentiation. Dev Dyn (2008) 1.12
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia (2010) 1.10
Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem (2003) 1.07
A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther (2002) 1.07
Advances in target therapy for lung cancer. Jpn J Clin Oncol (2009) 1.07
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer (2005) 1.05
Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol (2006) 1.03
Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res (2008) 1.03
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol (2009) 1.01
mTOR--beyond transplantation. Curr Opin Pharmacol (2005) 0.99
Light-harvesting function of carotenoids in photo-synthesis: the roles of the newly found 1(1)Bu- state. Biopolymers (2004) 1.09
Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren's syndrome showing only the LIP pattern radiologically. Intern Med (2012) 0.90
A comparison of head-out mist bathing, with or without facial fanning, with head-out half-body low-water level bathing in humans--a pilot study. Int J Biometeorol (2013) 0.90
Tracheobronchitis in a patient with Crohn's disease. Intern Med (2009) 0.87
Effects of isotonic and isometric exercises with mist sauna bathing on cardiovascular, thermoregulatory, and metabolic functions. Int J Biometeorol (2013) 0.84
Rapidly progressive respiratory failure in mixed connective tissue disease: report of an autopsy case. Intern Med (2012) 0.84
SIADH is only an atypical clinical feature in a patient with prolactinoma. Intern Med (2007) 0.83
Start and initial results of the Fukushima Prefecture acute myocardial infarction registration survey. Fukushima J Med Sci (2013) 0.79
Antisynthetase syndrome associated with sarcoidosis. Intern Med (2006) 0.78
[A case of airway-limiting type relapsing polychondritis]. Nihon Kokyuki Gakkai Zasshi (2007) 0.78
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Front Biosci (Landmark Ed) (2011) 0.78
Pathological findings and pulmonary dysfunction after acute respiratory distress syndrome for 5 years. Intern Med (2010) 0.77
A case of hypomyopathic dermatomyositis associated with rapid progressive interstitial pneumonia resistant to multi-immunosuppressive therapy. Am J Med Sci (2007) 0.76
Application of fluorescence resonance energy transfer (FRET) to investigation of light-induced conformational changes of the phoborhodopsin/transducer complex. Photochem Photobiol (2007) 0.76
[A case of constrictive bronchiolitis]. Nihon Kokyuki Gakkai Zasshi (2004) 0.75
Chronic diaphragmatic hernia. Gen Thorac Cardiovasc Surg (2007) 0.75
Large-cell neuroendocrine carcinoma without immunohistological positivity or serum elevation of CEA until relapse. Gen Thorac Cardiovasc Surg (2008) 0.75
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution. Chemotherapy (2017) 0.75
Thymic clear cell carcinoma. Gen Thorac Cardiovasc Surg (2010) 0.75
Adenocarcinoma arising in a mediastinal enteric cyst. Intern Med (2007) 0.75
[A case of desquamative interstitial pneumonia in the fibrotic stage]. Nihon Kokyuki Gakkai Zasshi (2009) 0.75
[A rare case of primary Sjögren's syndrome complicated by secondary lymphoid interstitial pneumonia]. Nihon Kokyuki Gakkai Zasshi (2009) 0.75
Assisted hatching of poor-quality bovine embryos increases pregnancy success rate after embryo transfer. J Reprod Dev (2011) 0.75
End-stage localized bronchiectasis mimicking a hemangioma. Gen Thorac Cardiovasc Surg (2009) 0.75
Extended sleeve lobectomy for interlobar lymph node metastasis invading the bronchus from peripheral lung cancer. Gen Thorac Cardiovasc Surg (2011) 0.75